Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

3.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.1K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

155
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
155
Clinical Trials01:16

Clinical Trials

6.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
6.9K
Blinding01:11

Blinding

2.5K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
2.5K
Randomized Experiments01:13

Randomized Experiments

7.1K
The randomization process involves assigning study participants randomly to experimental or control groups based on their probability of being equally assigned. Randomization is meant to eliminate selection bias and balance known and unknown confounding factors so that the control group is similar to the treatment group as much as possible. A computer program and a random number generator can be used to assign participants to groups in a way that minimizes bias.
Simple randomization
Simple...
7.1K
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.5K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Test of CP Symmetry in the Neutral Decays of Λ via J/ψ→ΛΛ[over ¯].

Physical review letters·2026
Same author

Precise Measurement of the Chromoelectric Dipole Moment of the Charm Quark.

Physical review letters·2026
Same author

Precise Measurement of Matter-Antimatter Asymmetry with Entangled Hyperon-Antihyperon Pairs.

Physical review letters·2026
Same author

Observation of Λ[over ¯]p→K^{+}π^{+}π^{-}π^{0} and Λ[over ¯]p→K^{+}π^{+}π^{-}2π^{0}.

Physical review letters·2026
Same author

First Measurement of the D_{s}^{+}→K^{0}μ^{+}ν_{μ} Decay.

Physical review letters·2026
Same author

Observation of the Electromagnetic Radiative Decays of the Λ(1520) and Λ(1690) to γΣ^{0}.

Physical review letters·2026

Related Experiment Video

Updated: Aug 11, 2025

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.3K

Design, power, and alpha levels in randomized phase II oncology trials.

A Haslam1, T Olivier2, V Prasad1

  • 1Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, USA.

ESMO Open
|February 3, 2023
PubMed
Summary

Many phase II oncology trials have flawed statistical reporting, leading to potentially ineffective drug testing or premature termination of beneficial therapies. Improved methodology and transparent reporting are crucial for reliable clinical trial outcomes.

Keywords:
clinical trialsreportingsample size calculations

More Related Videos

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.7K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.3K

Related Experiment Videos

Last Updated: Aug 11, 2025

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.3K
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.7K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.3K

Area of Science:

  • Oncology Clinical Trials
  • Biostatistics
  • Drug Development

Background:

  • Phase II trials are critical for balancing the risk of stopping effective drugs and continuing ineffective ones.
  • Recent phase II oncology trials require examination for methodological rigor and outcome interpretation bias.

Approach:

  • Retrospective cross-sectional analysis of full-length articles published on PubMed from January 2021 to June 2022.
  • Data extraction focused on sample size calculation, statistical parameters (power, alpha), outcomes, and authors' conclusions.

Key Points:

  • 5.4% of studies had power <80%, and 16.7% omitted power from sample size calculations.
  • 17.7% used a one-sided alpha level ≤0.025; 17.7% lacked a comparator for sample size determination.
  • 27.4% of studies reported positive conclusions despite not meeting primary endpoints or having equivocal results.

Conclusions:

  • Many randomized phase II oncology trials lack essential data for sample size calculations.
  • A significant number of trials did not use comparators for efficacy determination, even when randomized.
  • Positive conclusions were often drawn despite indeterminate results or unmet primary endpoints, indicating potential bias.